File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Pharmacokinetics (PK) and PK modeling of the first-in- class HBV core inhibitor NVR 3-778 dosed once- (QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients witn chronic HBV infection (CHBV)

TitlePharmacokinetics (PK) and PK modeling of the first-in- class HBV core inhibitor NVR 3-778 dosed once- (QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients witn chronic HBV infection (CHBV)
Authors
Issue Date2016
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016, November 11-15, 2016, Boston, USA, v. 64 n. S1, p. 931A-932A, abstract no. 1883 How to Cite?
DescriptionPoster Presentation
Persistent Identifierhttp://hdl.handle.net/10722/247873
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorKakuda, T-
dc.contributor.authorDel Bene, E-
dc.contributor.authorYuen, RMF-
dc.contributor.authorGane, EJ-
dc.contributor.authorKim, S-
dc.contributor.authorLiaw, S-
dc.contributor.authorBrown, N-
dc.contributor.authorKlumpp, K-
dc.contributor.authorFlores, F-
dc.contributor.authorChanda, S-
dc.date.accessioned2017-10-18T08:34:02Z-
dc.date.available2017-10-18T08:34:02Z-
dc.date.issued2016-
dc.identifier.citation67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016, November 11-15, 2016, Boston, USA, v. 64 n. S1, p. 931A-932A, abstract no. 1883-
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/247873-
dc.descriptionPoster Presentation-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatology-
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.titlePharmacokinetics (PK) and PK modeling of the first-in- class HBV core inhibitor NVR 3-778 dosed once- (QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients witn chronic HBV infection (CHBV)-
dc.typeConference_Paper-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.doi10.1002/hep.28800-
dc.identifier.hkuros281802-
dc.identifier.volume64-
dc.identifier.issueS1-
dc.identifier.spage931A-
dc.identifier.epage932A-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats